Literature DB >> 17623518

Cerebrotendinous xanthomatosis: case report with evidence of oxidative stress.

Luis F Gonzalez-Cuyar1, Brian Hunter, Peggy L R Harris, George Perry, Mark A Smith, Rudy J Castellani.   

Abstract

Cerebrotendinous xanthomatosis is an autosomal recessive disorder of bile acid synthesis, characterized by mutation in the mitochondrial enzyme 27-hydroxylase that leads to an accumulation of cholestanol and cholesterol. Characterized clinically by premature bilateral cataracts, slowly progressive neurological deterioration with dementia, cerebellar and brainstem signs, peripheral neuropathy, and seizures, the disease presents pathologically with lipid granulomata with foamy histiocytes and cholesterol clefts. Replacement therapy with chenodeoxycholic acid slows progression of the disease but does not reverse neurological deficits. Here, we present the case of a 49-year-old woman diagnosed at autopsy with cerebrotendinous xanthomatosis, on the basis of bilateral Achilles tendon granulomas, and typical foamy histiocytic infiltration of the brain, most severe in the dentate nucleus, and a typical clinical presentation. To investigate the pathological manifestations of this disease further, we performed immunohistochemistry for N(epsilon)-(carboxymethyl)-lysine, an indicator of oxidative damage, and found strong labeling of cytoplasmic material within histiocytes. In summary, this case of undiagnosed cerebrotendinous xanthomatosis during life emphasizes the need for a greater awareness of the disease, and early diagnosis and treatment. Further, the involvement of oxidative stress in cerebrotendinous xanthomatosis indicates that combined therapy with chenodeoxycholic acid and antioxidants may improve clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17623518     DOI: 10.1179/135100007X200173

Source DB:  PubMed          Journal:  Redox Rep        ISSN: 1351-0002            Impact factor:   4.412


  7 in total

Review 1.  Treatment of Smith-Lemli-Opitz syndrome and other sterol disorders.

Authors:  Melissa D Svoboda; Jill M Christie; Yasemen Eroglu; Kurt A Freeman; Robert D Steiner
Journal:  Am J Med Genet C Semin Med Genet       Date:  2012-10-05       Impact factor: 3.908

2.  Development of a bile acid-based newborn screen for Niemann-Pick disease type C.

Authors:  Xuntian Jiang; Rohini Sidhu; Laurel Mydock-McGrane; Fong-Fu Hsu; Douglas F Covey; David E Scherrer; Brian Earley; Sarah E Gale; Nicole Y Farhat; Forbes D Porter; Dennis J Dietzen; Joseph J Orsini; Elizabeth Berry-Kravis; Xiaokui Zhang; Janice Reunert; Thorsten Marquardt; Heiko Runz; Roberto Giugliani; Jean E Schaffer; Daniel S Ory
Journal:  Sci Transl Med       Date:  2016-05-04       Impact factor: 17.956

3.  Serial susceptibility weighted MRI measures brain iron and microbleeds in dementia.

Authors:  Wolff Kirsch; Grant McAuley; Barbara Holshouser; Floyd Petersen; Muhammad Ayaz; Harry V Vinters; Cindy Dickson; E Mark Haacke; William Britt; James Larseng; Ivan Kim; Claudius Mueller; Matthew Schrag; Daniel Kido
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

Review 4.  Natural history of neurological abnormalities in cerebrotendinous xanthomatosis.

Authors:  Janice C Wong; Kailey Walsh; Douglas Hayden; Florian S Eichler
Journal:  J Inherit Metab Dis       Date:  2018-02-26       Impact factor: 4.982

Review 5.  Psychiatric manifestations in cerebrotendinous xanthomatosis.

Authors:  M J Fraidakis
Journal:  Transl Psychiatry       Date:  2013-09-03       Impact factor: 6.222

6.  Cholesterotic Fibrous Histiocytoma in a Patient with Metabolic Syndrome.

Authors:  Masatoshi Deguchi; Setsuya Aiba
Journal:  Case Rep Dermatol       Date:  2017-08-17

Review 7.  Diagnostic and treatment implications of psychosis secondary to treatable metabolic disorders in adults: a systematic review.

Authors:  Olivier Bonnot; Hans Hermann Klünemann; Frederic Sedel; Sylvie Tordjman; David Cohen; Mark Walterfang
Journal:  Orphanet J Rare Dis       Date:  2014-04-28       Impact factor: 4.123

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.